Want to see AMRX full AI Analyst Report?
Top Page
Amneal Pharmaceuticals
(NASDAQ:AMRX)
Select Model
Select Model
Rating:61Neutral
Price Target:
$19.50
▲(8.82% Upside)
Action:Reiterated
Date:08/01/26
AMRX scores moderately due to improving operating results and upbeat, guidance-raising earnings commentary, supported by a clear technical uptrend. The score is held back primarily by balance-sheet risk (high debt and negative equity) and a demanding valuation (P/E ~37.6) with no dividend support.
Positive Factors
Improving revenue and cash generation
Amneal has grown revenue to roughly $3.05B TTM with materially stronger gross and EBITDA margins and positive free cash flow (~$205M). This sustained scale and FCF generation supports reinvestment, deleveraging and funding strategic initiatives over multiple quarters.
Negative Factors
High leverage and negative equity
Total debt near $2.69B and a negative equity position materially weaken balance-sheet flexibility. Even with recent interest savings, elevated leverage raises refinancing and covenant risk, slowing the pace at which the company can sustainably fund growth or withstand industry shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving revenue and cash generation
Amneal has grown revenue to roughly $3.05B TTM with materially stronger gross and EBITDA margins and positive free cash flow (~$205M). This sustained scale and FCF generation supports reinvestment, deleveraging and funding strategic initiatives over multiple quarters.
Read all positive factors
Amneal Pharmaceuticals (AMRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.85B
Dividend YieldN/A
Average Volume (3M)2.10M
Price to Earnings (P/E)37.6
Beta (1Y)0.79
Revenue Growth9.28%
EPS Growth4917.17%
CountryUS
Employees8,500
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.49
Shares Outstanding319,331,360
10 Day Avg. Volume1,923,215
30 Day Avg. Volume2,097,835
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)-55.77
Price to Sales (P/S)1.31
P/FCF Ratio14.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$19.25Price Target Upside7.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.97
Revenue Forecast (FY)$3.11B
Amneal Pharmaceuticals Business Overview & Revenue Model
Company Description
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized me...
How the Company Makes Money
Amneal makes money primarily by selling pharmaceuticals and related services across multiple revenue streams. (1) Generics: A significant portion of revenue comes from the sale of generic prescription drugs to wholesalers, distributors, pharmacies...
Amneal Pharmaceuticals Earnings Call Summary
Earnings Call Date:Jul 30, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational and financial momentum: double-digit revenue, EBITDA and EPS growth in Q2, raised full-year guidance, successful debt repricing, and a strategic acquisition (Kashiv) that meaningfully expands biosimilars capacity and pipeline. Commercial momentum in Specialty (CREXONT, BREKIYA) and multiple complex generic approvals/launches underpin the growth story. Near-term headwinds are limited: a flood-hit India site with an estimated ~$20M impact, a modest revenue decline in AvKARE, timing uncertainty for some biosimilar launches (e.g., XOLAIR), and increased near-term CapEx. Overall, positives (growth, guidance lift, strategic acquisition and capacity expansion) substantially outweigh the lowlights, supporting a constructive outlook.Positive Updates
Quarterly Revenue and Earnings Growth
Q2 total net revenue of $796M, up 10% year-over-year; adjusted EBITDA $206M, up 12%; adjusted EPS $0.30, up 20%.
Negative Updates
India Facility Flooding and Near-Term Impact
Severe rainfall and flooding in Gujarat impacted one manufacturing site; employees safe; company estimates approximately $20M of negative impact included in guidance with operations expected to resume in a few weeks.
Read all updates
Q2-2026 Updates
Positive
Negative
Quarterly Revenue and Earnings Growth
Q2 total net revenue of $796M, up 10% year-over-year; adjusted EBITDA $206M, up 12%; adjusted EPS $0.30, up 20%.
Read all positive updates
Company Guidance
Amneal reiterated strong Q2 results and raised its full‑year 2026 outlook: Q2 revenue was $796M with adjusted EBITDA of $206M and adjusted EPS of $0.30 (adjusted gross margin 46.2%, up 60 bps), Affordable Medicines revenue $490M (+13%), Specialty $149M (+17%) and AvKARE $157M (‑4%); new product launches added $45M in Q2 and first‑half results show total revenues +7%, adjusted EBITDA +16% and adjusted EPS +27%. Management increased FY2026 revenue guidance by $50M to $3.1B–$3.2B, raised adjusted EBITDA to $750M–$780M (+$10M) and nudged adjusted EPS to $0.96–$1.06 (+$0.01), while raising CapEx to ~ $150M (from ~$110M) and maintaining operating cash‑flow guidance; the plan incorporates an estimated $20M negative impact from the India flood. On financing and leverage, the Term Loan B was repriced (‑50 bps, ≈$12M annual interest savings) with a one‑notch credit upgrade and a path to net leverage below 3x by 2028. Finally, the pending Kashiv acquisition (expected to close soon) is expected to deliver $400M–$500M of financial benefits, expand drug‑substance capacity from ~26,000 L (end 2026) to ~75,000 L (2028), bring a >20‑program biosimilars pipeline (targeting ~6 commercial biosimilars by 2027 within a ~$14B TAM), and the guidance conservatively reflects a Q3 lanreotide goal date while XOLAIR is not included for FY26.Amneal Pharmaceuticals Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
38
Negative
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.12B | 3.02B | 2.79B | 2.39B | 2.21B | 2.09B |
| Gross Profit | 1.23B | 1.14B | 1.02B | 863.87M | 791.46M | 768.97M |
| EBITDA | 642.87M | 603.87M | 439.77M | 500.78M | 440.21M | 401.10M |
| Net Income | 157.60M | 72.06M | -116.89M | -83.99M | -129.99M | 10.62M |
Balance Sheet | ||||||
| Total Assets | 3.78B | 3.68B | 3.50B | 3.47B | 3.80B | 3.94B |
| Cash, Cash Equivalents and Short-Term Investments | 127.64M | 310.87M | 112.42M | 93.74M | 27.80M | 247.79M |
| Total Debt | 2.79B | 2.74B | 2.59B | 2.75B | 2.85B | 2.88B |
| Total Liabilities | 3.66B | 3.67B | 3.55B | 3.41B | 3.59B | 3.57B |
| Stockholders Equity | 33.02M | -70.79M | -109.27M | 19.78M | 298.42M | 360.34M |
Cash Flow | ||||||
| Free Cash Flow | 83.11M | 269.93M | 220.11M | 276.39M | -25.50M | 194.09M |
| Operating Cash Flow | 200.78M | 339.99M | 295.10M | 345.58M | 65.10M | 241.82M |
| Investing Cash Flow | -212.37M | -112.26M | -63.00M | -69.19M | -174.31M | -194.18M |
| Financing Cash Flow | 69.63M | -31.53M | -211.79M | -212.57M | -106.62M | -138.12M |
Amneal Pharmaceuticals Risk Analysis
Amneal Pharmaceuticals disclosed 58 risk factors in its most recent earnings report. Amneal Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Amneal Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $1.80B | 19.28 | 17.32% | ― | 37.03% | ― | |
71 Outperform | $41.33B | 55.53 | 9.30% | ― | 4.33% | ― | |
70 Outperform | $879.21M | 11.66 | 10.23% | ― | -1.39% | -41.70% | |
62 Neutral | $10.04B | 28.90 | 9.08% | 0.95% | -6.76% | -44.33% | |
61 Neutral | $5.85B | 37.58 | -327.25% | ― | 9.28% | 4917.17% | |
57 Neutral | $20.61B | -66.54 | -1.97% | 2.78% | 2.14% | 91.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
AMRX
Amneal Pharmaceuticals
18.32
10.36
130.15%
RDY
Dr Reddy's Laboratories
11.85
-1.86
-13.59%
VTRS
Viatris
17.56
8.96
104.16%
TEVA
Teva Pharmaceutical
35.01
19.32
123.14%
ANIP
ANI Pharmaceuticals
79.24
13.81
21.11%
AMPH
Amphastar Pharmaceuticals
19.94
-1.46
-6.82%
Amneal Pharmaceuticals Corporate Events
Business Operations and StrategyM&A TransactionsShareholder Meetings
Amneal Stockholders Approve Kashiv BioSciences Acquisition Plans
Positive
Jul 31, 2026
On July 31, 2026, Amneal Pharmaceuticals held a special meeting of stockholders at which holders of its Class A common stock approved all proposals related to the planned acquisition of Kashiv BioSciences, LLC under a Membership Interest Purchase ...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and Financing
Amneal Raises 2026 Outlook After Strong Q2 Results
Positive
Jul 30, 2026
For the second quarter ended June 30, 2026, Amneal reported net revenue of $796 million, up 10% year-on-year, with GAAP net income climbing 157% to $58 million and diluted EPS rising to $0.18. Growth was driven by strong performance in specialty p...
Executive/Board ChangesShareholder Meetings
Amneal Shareholders Back Board, Pay and Auditor at Meeting
Positive
May 7, 2026
Amneal Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on May 6, 2026, where shareholders voted on director elections, executive compensation and the company’s auditor. All nominated directors, including Deb Autor, the Pat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.